Denemek ALTIN - Özgür
Techade REDEFINING FUTURE OF life sciences industry
Bio Spectrum
|August 2021
Digital transformation is the topmost priority for global corporations and in a highly connected world that will remain largely contactless for an extended period, there are shifts in business models, customer experience, operations, and employee experience. With technology adoption accelerating across sectors, 2021 is likely to put the spotlight on the emergence of growth verticals in the life sciences sector namely healthcare, pharma, medical devices, diagnostics etc. India is now standing at the cusp of a re-imagined decade of technology, commonly being referred to as ‘Techade’. While we anticipate a significantly better global economic growth this year as compared to 2020, we are also very much looking forward to the enhancement being brought to the Indian life sciences industry as it continues its transformation journey in this redefined techade.
At a time when global output is estimated to have shrunk by 3.2 per cent, led by the ongoing pandemic, the technology sector in India rallied around to grow at 2.3 per cent year on year on the back of rapid acceleration in digital transformation and tech adoption. COVID -19 has indeed accelerated digital adoption across industries and technology service providers are witnessing a sharp growth in digital deals.
According to the National Association of Software & Services Companies (NASSCOM), the consolidated revenues of top listed technology companies recorded a growth of 5.3 per cent in the second half (H2) of 2020 over the first half (H1) of 2020. Further, with an increase in focus on digital upskilling initiatives, revenue per employee grew at 5.5 per cent in H2 2020 as compared to H1 2020.
Sharing his views, U.B. Pravin Rao, Chairman, NASSCOM, Bengaluru, says “Resonating with the overarching call-to-action for Atmanirbhar Bharat, domestic digital adoption intensified in 2020. With an increased focus on innovation, India witnessed more than 115,000 tech patents filed by companies in India in the last 5 years. The technology industry witnessed 146 M&A deals in 2020, 90 per cent of which were digitally focused. Also, companies saw a significant rise of 80 per cent in cloud adoption in second-half of 2020 compared to the first half.”
Bu hikaye Bio Spectrum dergisinin August 2021 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Bio Spectrum'den DAHA FAZLA HİKAYE
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.
3 mins
November 2025
Bio Spectrum
DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation
An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.
1 min
November 2025
Bio Spectrum
Abbott launches world's first dual-chamber leadless pacemaker system in India
Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.
1 min
November 2025
Bio Spectrum
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
November 2025
Translate
Change font size
